Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Als save search
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
Published: 2024-04-10 (Crawled : 10:00) - prnewswire.com
BCLI | $0.503 -6.99% -7.51% 1.1M
|
Health Technology
|
| O: -20.14%
H: 0.0%
C: 0.0%
als biomarker publication cell trial therapeutics
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
Published: 2024-04-09 (Crawled : 10:00) - prnewswire.com
BCLI | $0.503 -6.99% -7.51% 1.1M
|
Health Technology
|
| O: 10.45%
H: 0.0%
C: 0.0%
fda als cell for trial therapeutics agreement
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
Published: 2024-02-23 (Crawled : 11:00) - prnewswire.com
BCLI | $0.503 -6.99% -7.51% 1.1M
|
Health Technology
|
| O: 8.93%
H: 6.33%
C: -3.06%
nurown fda als cell trial therapeutics
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
Published: 2024-02-21 (Crawled : 13:30) - neurosense.investorroom.com
NRSN | News | $1.51 -5.63% -5.96% 270K
|
|
| O: -3.65%
H: 0.0%
C: -5.3%
als positive trial results
Sanofi, Denali ALS Candidate Flops in Mid-Stage Trial
Published: 2024-02-19 (Crawled : 13:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
candidate als trial
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
Published: 2024-01-09 (Crawled : 14:00) - biospace.com/
NRSN | News | $1.51 -5.63% -5.96% 270K
|
|
| O: 6.36%
H: 3.57%
C: -1.67%
primec disease als positive trial
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
Published: 2023-12-21 (Crawled : 12:00) - globenewswire.com
CLNN S | $0.3275 -3.56% -3.69% 1.2M
|
|
| O: -34.37%
H: 3.49%
C: -6.8%
au8 label als biomarker treatment extension trial platform
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
Published: 2023-12-14 (Crawled : 14:30) - neurosense.investorroom.com
NRSN | News | $1.51 -5.63% -5.96% 270K
|
|
| O: 27.94%
H: 6.9%
C: -0.01%
als trial
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
Published: 2023-12-05 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.51 -5.63% -5.96% 270K
|
|
| O: -30.2%
H: 20.19%
C: 8.65%
als trial phase 2
Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS
Published: 2023-12-04 (Crawled : 15:30) - biospace.com/
AMLX | $1.97 -1.5% -1.52% 1M
|
|
| O: 0.21%
H: 4.28%
C: 1.47%
amx0035 neuroinflammatory als publication pharmaceuticals biomarkers
NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023
Published: 2023-11-06 (Crawled : 13:30) - prnewswire.com
NRSN | News | $1.51 -5.63% -5.96% 270K
|
|
| O: 3.03%
H: 9.8%
C: 9.61%
als expected topline results
Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls
Published: 2023-09-25 (Crawled : 11:00) - globenewswire.com
CLNN S | $0.3275 -3.56% -3.69% 1.2M
|
|
| O: 4.51%
H: 9.53%
C: -4.11%
cnm-au8 als treatment trial platform
BrainStorm Touts Biomarker Data for ALS Candidate After Two FDA Rebuffs
Published: 2023-07-10 (Crawled : 15:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
| Email alert
Add to watchlist
fda candidate als biomarker
Clene’s CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial
Published: 2023-06-15 (Crawled : 20:00) - globenewswire.com
CLNN S | $0.3275 -3.56% -3.69% 1.2M
|
|
| O: -20.0%
H: 14.88%
C: 1.44%
au8 als trial platform
NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023
Published: 2023-06-01 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.51 -5.63% -5.96% 270K
|
|
| O: -2.56%
H: 5.26%
C: 3.29%
business als expected topline trial financial results
NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
Published: 2023-05-15 (Crawled : 13:00) - prnewswire.com
NRSN | News | $1.51 -5.63% -5.96% 270K
|
|
| O: 3.34%
H: 1.86%
C: -3.23%
als trial
NeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment
Published: 2023-04-17 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.51 -5.63% -5.96% 270K
|
|
| O: -4.29%
H: 5.13%
C: 2.56%
ceo als trial
CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial
Published: 2023-03-09 (Crawled : 03:00) - globenewswire.com
CLNN S | $0.3275 -3.56% -3.69% 1.2M
|
|
| O: 10.0%
H: 0.7%
C: -5.59%
au8 six als trial platform
Clene's Nanocrystal ALS Treatment Bounces Back with Positive Data
Published: 2023-03-09 (Crawled : 18:00) - biospace.com/
CLNN S | $0.3275 -3.56% -3.69% 1.2M
|
|
| O: 10.0%
H: 0.7%
C: -5.59%
treatment als back positive
Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial
Published: 2023-03-08 (Crawled : 03:00) - globenewswire.com
CLNN S | $0.3275 -3.56% -3.69% 1.2M
|
|
| O: 10.0%
H: 0.7%
C: -5.59%
au8 als trial platform
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.